Advanced Squamous NSCLC Survival Improved With Chemoimmunotherapy Regardless of PD-L1 Expression
July 20th 2022During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.
Roundtable Discussion: McKay Examines Second- and Third-Line Therapy for Metastatic RCC
July 20th 2022During a Targeted Oncology case-based roundtable event, Rana R. McKay, MD, discussed the case of a patient who progressed following treatment with axitinib and pembrolizumab for clear cell renal cell carcinoma.
Roundtable Discussion: Mohamed Analyzes Data for Understanding ES-SCLC Treatment
July 18th 2022During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.
Anderson Reviews Data for Belantamab Mafodotin as Later-Line Therapy for Multiple Myeloma
July 18th 2022During a Targeted Oncology case-based roundtable event, Larry D. Anderson, MD, PhD, discussed the results of the DREAMM-2 trial and management of belantamab mafodotin for patients with multiple myeloma.
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
July 15th 2022During a live virtual event, Ulka N. Vaishampayan, MBBS, discussed the choice of first-line therapy for clear cell renal cell carcinoma and whether the approach to treatment would change with other disease histologies.
Khan Reviews Later-Line Therapy Options for DLBCL With Subgroup Considerations
July 10th 2022During a Targeted Oncology case-based roundtable event, Cyrus M. Khan, MD, discussed the data supporting the use of polatuzumab, bendamustine, and rituximab, tasfasitamab plus lenalidomide, and loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.
Roundtable Discussion: Barata Explores Second- and Third-Line Options for Recurrent RCC
July 8th 2022During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed the case of a patient with clear cell renal cell carcinoma who progressed following frontline treatment with axitinib/pembrolizumab.
VISION Trial Shows Survival Benefit of Lutetium Radioligand for mCRPC
July 5th 2022During a live virtual event, Emmanuel S. Antonarakis, MD, discussed the VISION trial supporting the use of 177-lutetium-PSMA-617 for patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles from this event.
Burger Details the Data to Help Choose Treatment in Chronic Lymphocytic Leukemia
July 3rd 2022During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.
Chao Discusses Stratifying and Treating Patients With Graft-Vs-Host Disease
June 27th 2022During a Targeted Oncology case-based roundtable event, Nelson Jen An Chao, MD, discussed risk management and treatment of patients with steroid-refractory acute graft-versus-host-disease as well as chronic graft-versus-host disease.
Lee and McGregor Discuss Methods to Integrate New Approaches in RCC Treatment
June 25th 2022During a Targeted Oncology case-based event, Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection.
Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC
June 22nd 2022During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.